Jung, Ki Sun; Cho, Su-Hee; Kim, Seok Jin; Ko, Young Hyeh; Kang, Eun-Suk; Kim, Won Seog
Journal of hematology & oncology
2016NA ; 9 ( 3 ) :41.
PMID : 27091029
ÀúÀÚ »ó¼¼Á¤º¸
Jung, Ki Sun -
Cho, Su-Hee -
Kim, Seok Jin -
Ko, Young Hyeh -
Kang, Eun-Suk -
Kim, Won Seog -
ABSTRACT
Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but optimal treatment is unclear. Therefore, we analyzed the efficacy of L-asparaginase-based regimens for ANKL patients. Twenty-one patients who received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) or etoposide, ifosfamide, dexamethasone, and L-asparaginase (VIDL) chemotherapy at Samsung Medical Center were selected. The overall response rate for all patients was 33% (7/21); 38% (5/13) in SMILE and 40% (2/5) in VIDL, respectively. The median progression-free survival was 3.9 months (95% CI 0.0-8.1 months) and median overall survival was 7.0 months (95% CI 2.3-11.7 months). Treatment response (P?=?0.001), hematopoietic stem cell transplantation (HSCT) (P?=?0.007) and negative conversion of Epstein-Barr virus (EBV) DNA titer after treatment (P?=?0.004) were significantly associated with survival. Thus, L-asparaginase-based regimens followed by allogeneic HSCT seem to improve the outcome for ANKL patients.
keyword
ANKL; Allogeneic HSCT; L-asparaginase; Response; Survival
¸µÅ©